Home
About Leecan
Overview of Leecan
History
Corporate Culture
Honor
Responsibility
Product
Marketed Products
Regulatory Review
In Development
Production and Research Platform
Research and Development Platform
Production and Operation
Quality Assurance
CMO/CDMO
News regulations
Investor
Careers
Talent Concept
People in leecan
Recruitment
Career development
Contact Us
Cooperation
Supplier Cooperation
Recruitment
Pharmacovigilance
CMO/CDMO
EN
/
CN
Home
About Leecan
Overview of Leecan
History
Corporate Culture
Honor
Responsibility
Product
Marketed Products
Regulatory Review
In Development
Production and Research Platform
Research and Development Platform
Production and Operation
Quality Assurance
CMO/CDMO
News regulations
Investor
Careers
Talent Concept
People in leecan
Recruitment
Career development
Contact Us
Cooperation
Supplier Cooperation
Recruitment
Pharmacovigilance
CMO/CDMO
Issue 12: Quick Overview of NMPA/CDE Regulations for May-June
Release time：2026-07-08
share:
Previous article：Issue 13: Monthly Report on Core Policies of Pharmaceutical Regulations for June-July 2026
next article：Issue 11: Key Updates in Medical and Pharmaceutical Regulations for Early to Mid-2026
Back to list
You may also want to read
Two specifications of bendamustine hydrochloride for injection have obtained drug production approval!
2025.01.06
CMO/CDMO services
2025.05.27
Strengthen management to ensure safety, delve into details to enhance quality -The "Safety and Quality Month" campaign by Leecan Pharmaceuticals has been successfully concluded!
2025.12.31
